Published in Cancer Weekly, July 31st, 2001
Z.H. Qiu and colleagues at the Beijing Institute for Radiation Medicine in Beijing, combined two methods of treating laryngeal cancer in hopes of achieving additive antitumor effects. They constructed an adenovirus vector expressing both wild-type p53 and granulocyte-macrophage colony-stimulating factor (GM-CSF). The vector (Ad-p53/GM-CSF) was transfected into human laryngeal cancer cells, Hep-2, and the results were reported in Cancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.